Results 121 to 130 of about 49,324 (252)
American Journal of Hematology, Volume 101, Issue 1, Page 97-109, January 2026.ABSTRACT D‐dimer defines degradation products derived from the proteolysis mediated by plasmin on cross‐linked fibrin. The evidence‐based use of D‐dimer in some conditions has been consolidated. Currently, however, there is an entrenched prescription of D‐dimer testing to screen otherwise healthy subjects that may induce prescribing physicians to start
Armando Tripodi +11 more
wiley +1 more source
High-levelexpression of functional recombinant human coagulation factor VII in insect cells [PDF]
: Recombinant coagulation factor VII (FVII) is used as a potential therapeutic intervention in hemophilia patients who produce antibodies against the coagulation factors.
AD Shapiro +30 more
core +1 more source
Circulating Factor IX Antigen-Inhibitor Complexes in Hemophilia B- Following Infusion of a Factor IX Concentrate [PDF]
, 1977 Scott H. Goodnight +3 more
openalex +1 more source
Biotechnology and Bioengineering, Volume 123, Issue 1, Page 5-25, January 2026.Proteomic analysis of CHO cells under mild hypothermia (31°C) reveals ER stress responses, ubiquitination dynamics, and adaptive mechanisms. Magnetic immuno‐affinity enrichment and mass spectrometry highlight protein regulation differences in non‐producer versus producer cells, offering insights for optimising biopharmaceutical production of IgG1 and ...
David Ryan +5 more
wiley +1 more source
Treatment of hemophilia B: focus on recombinant factor IX
Biologics: Targets & Therapy, 2013 Massimo Franchini, Francesco Frattini, Silvia Crestani, Cinzia Sissa, Carlo BonfantiDepartment of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, ItalyAbstract: Hemophilia B is a recessive X-linked bleeding disorder characterized by ...
Franchini M +4 more
doaj
Biotechnology and Bioengineering, Volume 123, Issue 1, Page 174-185, January 2026.ABSTRACT To enable adeno‐associated viral vectors (AAV) to achieve their maximum potential, next‐generation manufacturing processes must be developed to make gene therapies more affordable and accessible. This study focused on the design of two different intensified AAV downstream manufacturing processes at bench and pilot scale.
Akshay S. Chaubal +6 more
wiley +1 more source
Delivery of human apolipoprotein (apo) E to liver by an [E1(-), E3(-), polymerase(-), pTP(-)] adenovirus vector containing a liver-specific promoter inhibits atherogenesis in immunocompetent apoE-deficient mice [PDF]
, 2006 Recombinant adenovirus (rAd)-mediated apoE gene transfer to the liver of apoE(-/-) mice is anti-atherogenic. However, first generation rAd vectors were associated with immune clearance of transduced hepatocytes, while an improved [E1(-), E3(-) polymerase(
Amalfitano, A +4 more
core
Gene Therapy for the Treatment of Hemophilia B Using PINC-Formulated Plasmid Delivered to Muscle with Electroporation [PDF]
, 2001 Jason G. Fewell +6 more
openalex +1 more source
European Journal of Haematology, Volume 116, Issue 1, Page 66-74, January 2026.ABSTRACT Objectives We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) treated on demand with recombinant von Willebrand factor (rVWF) in the United Kingdom. Methods Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first‐time rVWF for the on‐demand ...
Mike Laffan +6 more
wiley +1 more source
European Journal of Haematology, Volume 116, Issue 1, Page 75-84, January 2026.ABSTRACT Objectives We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) receiving recombinant von Willebrand factor (rVWF) in surgical settings in the United Kingdom. Methods Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first‐time rVWF for the ...
Mike Laffan +6 more
wiley +1 more source